Skip to main content

Table 1 Characteristics of included meta-analyses

From: Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009

AuthorJournal/year2016 impact factorNumber of drug RCTs in meta-analysisPublication dates of articles reviewedSetting/diagnosisPharmacological interventionComparison arm(s)Efficacy/harmFunding sourceNumber of authors with disclosed industry financial ties/number of authorsNumber of authors employed by industry/number of authors
General medicine
Feller et al. [23]JAMA/201844.4211984–2017Non-pregnant adults with subclinical hypothyroidismThyroid hormone therapyPlacebo, no interventionEfficacy and harmNon-industry0/150/15
McIntyre et al. [24]JAMA/201844.4231999–2017Patients with distributive shockVasopressin—4 included plus catecholamine vasopressorsCatecholamines vasopressors—2 includedEfficacyNot reported2/100/10
Zheng et al. [25]JAMA/201844.42362004–2017Patients with type 2 diabetesNMA: SGLT-2 inhibitors, GLP-1 agonists, DPP-4 inhibitorsPlacebo, no treatmentEfficacy and harmNot reported1/70/7
Cipriani et al. [26]Lancet/201847.85221979–unpublishedAdults with major depressive disorderNMA: antidepressants—21 includedPlaceboEfficacy and harmNon-industry4/180/18
Gayet-Ageron et al. [27]Lancet/201847.822010–2017Patients with acute severe hemorrhageTranexamic acidPlaceboEfficacy and harmNot reported0/60/6
Jinatongthai et al. [28]Lancet/201747.8401986–2005Patients with ST-segment elevation myocardial infarctionNMA: fibrinolytic agents—4 included, parenteral anticoagulants—4 included, Gp IIb/IIIa inhibitors—3 included, antiplatelets—3 includedN/AEfficacy and harmNo study funding0/80/8
Alibhai et al. [29]Ann Intern Med/201717.223a2001–2014Men with non-metastatic prostate cancerBisphosphonates—5 includedPlaceboEfficacyNon-industry3/90/9
Wilson et al. [30]Ann Intern Med/201717.210b2003–2012Adults with chronic kidney diseaseBisphosphonates—4 included, raloxifene, denosumab, teriparatidePlacebo, no treatment, active controlEfficacy and harmNon-industry0/80/8
Baxi et al. [31]BMJ/201820.8132015–2017Patients with cancer with recurrent or metastatic diseaseAntiPD-1—3 includedChemotherapy drug, small molecule inhibitor, investigators’ choiceHarmNon-industry0/70/7
López-López et al. [32]BMJ/201720.8231989–2014Adults with non-valvular atrial fibrillation eligible for oral anticoagulationDOACs—5 includedWarfarin or other vitamin K antagonist, aspirin, clopidogrelEfficacy and harmNon-industry0/180/18
Sadeghirad et al. [33]BMJ/201720.8101993–2017cPatients with sore throatCorticosteroids—3 includedPlacebo, standard careEfficacyNo study funding0/90/9
Specialty journals
McCarthy et al. [34]J Clin Oncol/201724.032012–2014Patients with newly diagnosed multiple myelomaLenalidomidePlacebo or observationEfficacy and harmIndustry-financial support and resourced15/194/19
van Beurden-Tan et al. [35]J Clin Oncol/201724.0172005–2016Adults with relapsed and/or refractory multiple myelomaNMA: 18 treatments for multiple myelomaN/AEfficacyNon-industry5/50/5
Abdel-Qadir et al. [36]Ann Oncol/201711.9161983–2013Adults with cancerNMA: dexrazoxane, angiotensin antagonist, beta-blockers, statins, co-enzyme Q-10, prenylamine, N-acetylcysteinePlacebo or no treatmentEfficacyNot reported0/70/7
Siontis et al. [37]Circulation/201719.342014–2016Patients with valvular heart diseaseDOAC—4 includedWarfarinEfficacy and harmNot reported1/40/4
Renda et al. [38]J Am Coll Cardiol/201719.942009–2013Patients with atrial fibrillation and valvular heart diseaseNOAC—4 includedWarfarinEfficacy and harmNot reported3/40/4
Lau et al. [39]J Am Coll Cardiol/201719.972007–2015Patients with coronary artery diseasePotent P2Y12 inhibitors—3 types includedPlacebo or clopidogrelEfficacy and harmNot reported13/160/16
Respiratory medicine
Verberkt et al. [40]Eur Respir J/201710.622e1982–2015Patients with chronic breathlessness due to advanced diseaseOpioids—8 includedPlaceboEfficacyNon-industry3/90/9
Ding et al. [41]J Thorac Oncol/201710.3162008–2015Treatment-naive patients with advanced EGFR-mutant non-small cell lung cancerEGFR TKI—3 includedEGFR TKI—3 includedEfficacy and harmNot reported0/80/8
Lee et al. [42]J Thorac Oncol/201710.332015–2016Patients with metastatic EGFR-mutated non-small cell lung cancerImmune checkpoint inhibitors—3 includedDocetaxelEfficacyNot reported0/70/7
Bethel et al. [43]Lancet Diabetes Endocrinol/201819.742015–2017Adults with type 2 diabetesGLP-1 receptor agonists—4 includedPlaceboEfficacy and harmIndustry-financial support15/173/17
de Carvalho et al. [44]Diabetes Care/201811.9202012–2016Participants with familial or non-familial hypercholesterolemiaPCSK9 inhibitors—3 includedPlacebo, ezetimibe, atorvastatin, rosuvastatin, standard therapyEfficacyNot reported0/30/3
Maiorino et al. [45]Diabetes Care/201711.9262011–2016Adults with type 2 diabetesInsulin regimens plus GLP-1 receptor agonistsInsulin regimensEfficacyNot reported2/60/6
Khera et al. [46]Gastroenterology/201818.4281998–2015Obese or overweight adultsNMA: orlistat, lorcaserin, naltrexone-bupropion, liraglutide, phentermine-topiramateAlternate treatment or placeboEfficacyNo study funding0/90/9
Nelson et al. [47]GUT/201716.7212003–2015Adults with chronic idiopathic constipationNMA: diphenyl methanes or derivatives—2 included, 5-HT4 receptor agonists—3 included, GC-C receptor agonist—1 included, chloride channel type 2 opener—1 included, apical sodium bile acid—1 includedN/AEfficacyNot reported1/90/9
Ford et al. [48]GUT/201716.7131986–2015Adults (participants aged > 16 years) with functional dyspepsiaPsychotropic drugs—6 classesPlaceboEfficacy and harmNot reported0/60/6
Cochrane reviews          
Tenforde et al. [49]Cochrane Database Syst Rev/20186.3131997–2018Adults with HIV-associated cryptococcal meningitisNMA: antifungal drugs, adjunctive drugsN/AEfficacy and harmNon-industry1/70/7
McNicol et al. [50]Cochrane Database Syst Rev/20186.311f1992–2012Pediatric patients with postoperative painKetorolacPlacebo, opioidHarmNon-industry1/30/3
Normansell et al. [51]Cochrane Database Syst Rev/20186.34g1974-2016Adults and children with exacerbations of asthmaMacrolide antibiotics—3 included, penicillin—2 includedPlaceboEfficacy and harmNon-industry0/60/6
  1. 5-HT4 5-hydroxytryptamine receptor 4, DOAC direct-acting oral anticoagulant, DPP-4 dipeptidyl peptidase 4, EGFR epidermal growth factor receptor, GC-C guanylate cyclase C, GLP-1 glucagon-like peptide-1, Gp IIb/IIIa glycoprotein IIb/IIIa, N/A not applicable (no placebo or no treatment arm in NMA), NMA network meta-analysis, NOAC non-vitamin K antagonist oral anticoagulants, PCSK9 proprotein convertase subtilisin/kexin type 9, PD-1 programmed cell death protein 1, SGLT-2 sodium-glucose cotransporter 2, TKI tyrosine kinase inhibitors
  2. aThe systematic review included 27 RCTs in total, of which 23 had their results pooled
  3. bThe systematic review included 13 RCTs in total, of which 10 had their results pooled
  4. cThe date for 1 of the included RCTs was reported as 1994 in a single figure and 1993 in all other instances; therefore, 1993 was used as the beginning of the date range of included studies
  5. dThe systematic review included an acknowledgment thanking Kristina Hernandez and Peter Simon for medical writing assistance, sponsored by Celgene Corporation, which was coded as industry funding in the form of resources
  6. eThe systematic review included 35 RCTs in total, of which 22 had their results pooled
  7. fThe systematic review included 13 RCTs in total, of which 11 had their results pooled
  8. gThe systematic review included 6 RCTs in total, of which 4 had their results pooled